U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy

    NEXT STORY
    SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2019 Financial Results
    PREV STORY
    CorMedix Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042

    TSR-042 is the first TESARO immuno-oncology candidate to enter a registration programOngoing clinical trial ...

    author_avatar
    NASDAQ Market News

    Elias Zerhouni, President of Sanofi R&D, wins ‘Executive of the Year’ at annual Scrip Awards

    Press ReleaseSource: Sanofi (EURONEXT: SAN) (NYSE: SNY) Elias Zerhouni, President of Sanofi R&D, wins ...

    author_avatar
    NASDAQ Market News

    Aptose Biosicences and CrystalGenomics Announce Issuance of U.S. Patent for CG’806

    SAN DIEGO and TORONTO and SEOUL, South Korea, Sept. 12, 2017 (GLOBE NEWSWIRE) -- ...

    author_avatar
    NASDAQ Market News